Building A Path To A Successful AAV Product

Adeno‑associated viruses (AAVs) have become leading vectors in gene therapy, but their successful development requires robust analytical strategies and careful monitoring of critical quality attributes. This webinar provides an in‑depth overview of current state‑of‑the‑art analytical methods used to characterize AAVs throughout manufacturing and drug product development. Prof. Dr. Susumu Uchiyama discusses how selecting the right analytical tools for each attribute supports process optimization and ensures product quality, highlighting parameters that must be closely followed during development.

The session also features case studies demonstrating practical methods to evaluate infectivity and quantify the full‑to‑empty capsid ratio using orthogonal techniques such as analytical ultracentrifugation and mass photometry. These insights reveal how complementary approaches strengthen data reliability and provide a clearer understanding of vector potency and consistency.

Learn which analytical methods best support AAV characterization, which quality attributes matter most, and how infectivity can be measured independent of the encoded therapeutic protein—key considerations for advancing high‑quality AAV products.